JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M203248200 on May 6, 2002

J. Biol. Chem., Vol. 277, Issue 28, 25457-25464, July 12, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/28/25457    most recent
M203248200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marella, M.
Right arrow Articles by Chabry, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marella, M.
Right arrow Articles by Chabry, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Filipin Prevents Pathological Prion Protein Accumulation by Reducing Endocytosis and Inducing Cellular PrP Release*

Mathieu MarellaDagger , Sylvain Lehmann§, Jacques Grassi, and Joëlle ChabryDagger ||

From the Dagger  Institut de Pharmacologie Moléculaire et Cellulaire, Unité Mixte de Recherche 6097, Centre National de la Recherche Scientifique, 660 Route des Lucioles, 06560 Valbonne, France, the § Institut de Génétique Humaine, Centre National de la Recherche Scientifique, 34396 Montpellier, France, and the  Service de Pharmacologie et d'Immunologie, Commisariat à l'Energie Atomique, 91191 Gif-sur-Yvette, cedex, France

Received for publication, April 5, 2002, and in revised form, April 24, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Conversion of the normal membrane-bound prion protein (PrP-sen) to its pathological isoform (PrP-res) is a key event in the pathogenesis of transmissible spongiform encephalopathies. Although the subcellular sites of conversion are poorly characterized, several lines of evidence have suggested the involvement of membrane lipid rafts in the conversion process. Here we report that copper stimulates the endocytosis of PrP-sen via a caveolin-dependent pathway in both microglia and neuroblastoma cells. We show that the polyene antibiotic filipin both limits endocytosis of PrP-sen and dramatically reduces the amount of membrane-bound PrP-sen. This reduction results from a rapid and massive release of full matured PrP-sen into the culture medium. Finally, we demonstrate that filipin is a potent inhibitor of PrP-res formation into chronically infected neuroblastoma cells. Our results reinforce the role of rafts in PrP trafficking and raise the possibility that the release of PrP-sen from the plasma membrane decreases the amount of available substrate PrP-sen at the conversion sites.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transmissible spongiform encephalopathies (TSE)1 are infectious neurodegenerative diseases including scrapie of sheep, bovine encephalopathy in cattle, and a variety of human diseases such as Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheincher syndrome, and fatal familial insomnia. TSE are associated with the conversion of the protease-sensitive normal isoform of the prion protein (PrP-sen) to a pathological scrapie isoform named PrPsc or PrP-res based on its protease resistance. No differences in distribution charges and amino-terminal sequences have been detected between the isoforms (1); however, PrP-sen and PrP-res conformations differ markedly (2). PrP-sen is a protease-sensitive monomeric protein, whereas PrP-res forms highly insoluble aggregates characterized by their resistance to proteolytic digestion (3). The conversion may occur via a post-translational process without any chemical modifications of the molecules (4, 5). Direct interactions between PrP-sen and PrP-res aggregates and the conversion process resulting from it are molecular key events in the development of TSE pathogenesis.

PrP-sen is bound to the external surface of the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. Like most GPI-anchored proteins, PrP-sen is clustered into cholesterol- and sphingomyelin-rich domains called rafts or caveolae-rich domains, referring to the presence of the protein marker caveolin (6, 7). However, it has been shown that cells poorly expressing caveolin such as neuroblastoma cells (N2a) also contain rafts based on the existence of detergent-resistant membranes enriched for GPI-anchored proteins (8). Caveolae domains are involved in a variety of physiological and pathological situations such as signal transduction (9) and entry of nonenveloped DNA virus SV40, respectively (10, 11). From the plasma membrane, PrP-sen either can be endocytosed, recycled, and degraded or can bind to PrP-res and thus be converted into newly formed PrP-res aggregates (for review see Ref. 12). The subcellular sites for binding of PrP-sen to PrP-res and conversion remain unknown. These events could occur either on the cell surface or into nondefined endocytosis organelles during PrP-sen trafficking (13, 14). Recently, Baron et al. (15) have shown that raft-bound PrP-sen can be substrate for conversion only when PrP-res molecules are themselves inserted into contiguous membranes. Once PrP-res is formed, it appears to accumulate on the surface of cells (6) and/or into lysosomes (13). Both sterol-binding antibiotics amphotericin B and lovastatin, which decrease the membrane cholesterol level, inhibit the formation of PrP-res in scrapie-infected N2a cells (16, 17). Likewise, the replacement of the GPI anchor of PrP by a transmembrane domain targets mutated PrP to clathrin-coated pits, resulting in the decrease of PrP-res formation (18). Collectively, these reports strongly support the idea that rafts could be the sites for conversion and PrP-res accumulation.

The PrP-sen amino terminus contains a series of histidine- and glycine-rich octapeptide repeats that are copper ion-binding sites (19). Interestingly, cooper ions stimulate endocytosis of PrP-sen (20), suggesting that PrP could serve as a chelator for uptake and delivery of copper ions to intracellular targets. Alternatively, copper ions could be essential cofactors for some yet unknown physiological functions of PrP-sen.

Here we have assessed the copper-induced endocytosis of PrP-sen using two complementary approaches. First, by immunolocalization and confocal laser microscopy observation, we show that copper stimulates PrP-sen endocytosis through a caveolin-dependent pathway in both human microglia and mouse neuroblastoma cells. Second, we demonstrate that the binding of a radiolabeled PrP-recognizing monoclonal antibody can be used to assess quantitatively internalization of membrane-bound PrP-sen. Moreover, we show that the polyene antibiotic filipin that binds to membrane sterols both inhibits PrP endocytosis and provokes the release of the PrP molecules from the plasma membrane. As a result, filipin is found to be a potent inhibitor of PrP-res formation in scrapie-infected N2a cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents and Antibodies-- Proteinase K and Pefabloc® were purchased from Roche Molecular Biochemicals. Dulbecco's modified Eagle's medium (DMEM), Opti-MEM, trypsin, and Geneticin G418 were from Invitrogen, and fetal bovine serum (FBS) was from Biomedia. Fresh solutions of chlorpromazine, nystatin, and filipin (Sigma) were prepared every day. Mouse monoclonal antibodies SAF32 and SAF70 were raised in knock-out mice (21) by immunizing with a scrapie-associated fibrils (SAF) preparation obtained from infected hamster brain (263K strain). SAFs were denaturated before immunization by treatment with formic acid. Monoclonal antibody SAF32 was directed against the entire octarepeat region, whereas SAF70 recognized the 142-160 sequence (22). Both antibodies cross-react with PrP from most mammalian species (bovine, ovine, mouse, hamster, and human). Monoclonal antibodies Pri-308 was raised in Biozzi's mice by immunizing with a synthetic peptide representative of the human 106-126 sequence (22) and binds only PrP from human and hamster. Rabbit polyclonal antibody R30 was raised against the synthetic prion peptide 89-103 of the mouse sequence. The anti-caveolin-1 antibody was from Santa Cruz. Secondary antibodies conjugated to peroxidase, fluorescein isothiocyanate, or Texas Red and Alexa 488-transferrin were from Jackson ImmunoResearch (West Grove, PA).

Cell Culture-- The human microglia cell line C13-NJ, a generous gift of Dr. Tardieu (Le Kremlin-Bicêtre, France), was established after transfection of large T antigens and was cultivated into DMEM supplemented with 10% FBS and penicillin-streptomycin (23). Neuroblastoma 3F4-N2a cells overexpressing murine PrP in which residues 108 and 110 were replaced by methionine were cultivated as described previously (24). Neuroblastoma N2a cells overexpressing mouse PrP (subclone 58) were cultivated in Opti-MEM containing 10% inactivated FBS, penicillin-streptomycin, and 1 mg/l G418. This cell line has been chronically infected with Chandler strain-infected mouse brain and was named N2aS12 sc+ (25). Because the treatment of N2aS12 sc+ cells with Congo Red (1 µg/ml) allowed the total cure of the cells of PrP-res, Congo Red-treated N2aS12 cells were used here as a control. The cells were maintained at 37 °C in 5% CO2 atmosphere in a biohazard laboratory and were split every 4 days at a 1:5 ratio.

Confocal Microscopy-- The day before the experiment, C13-NJ, 3F4-N2a, and N2aS12 cell lines were grown on glass coverslips (Lab-Tek) in DMEM supplemented with 10% FBS. For cell surface PrP-sen detection experiments, coverslips were washed twice with phosphate-buffered saline (PBS) and then incubated in DMEM containing 10% FBS in the absence or in the presence of filipin (5 µg/ml), nystatin (50 µg/ml) for 15 min, or chlorpromazine (5 µg/ml) for 30 min at 37 °C. To stimulate endocytosis of cell surface PrP, CuSO4 was added to the medium to a final concentration of 500 µM for 30 min. Then the cells were washed three times with PBS and fixed in paraformaldehyde 3% in PBS for 10 min or 20 min for the N2aS12 and C13-NJ cell lines, respectively. The cells were washed twice with PBS and then incubated in PBS containing 50 mM NH4Cl for 10 min to quench excess of free aldehyde groups. After 20 min in PBS with 10% inactivated horse serum (HS), each coverslip was incubated for 90 min in PBS with 5% HS containing appropriate antibodies (Pri308 diluted 1:300; R30 diluted 1:500; SAF70 diluted 1:300; and anti-caveolin-1 diluted 1:500). The cells were rinsed three times in PBS and then incubated with the appropriate conjugated secondary antibodies (1/600) in PBS with 5% HS for 45 min. When indicated, the incubations with secondary antibodies were done on permeabilized cells, i.e. in PBS with 5% HS supplemented with 0.1% Triton X-100.

For the endocytosis studies, the PrP-sen was immunodetected by incubating the cells with the indicated antibodies in PBS containing 1% bovine serum albumin for 90 min at 37 °C. Transferrin receptors or caveolae were detected with 50 µg/ml iron-saturated Alexa 488-transferrin or a 1:300 diluted anti-caveolin-1 antibody, respectively. The endocytosis of PrP-sen was initiated by incubating cells with a 500 µM solution of CuSO4 for 30 min at 37 °C. The cells were then washed three times with PBS and fixed in PBS containing 3% paraformaldehyde for 10 min or 20 min for the N2aS12 and C13-NJ cell lines, respectively. The coverslips were washed twice with PBS, quenched with PBS containing 50 mM NH4Cl, and incubated with the conjugated secondary antibodies in PBS with 5% HS with 0.1% Triton X-100. After three washes in PBS and one wash in distilled water, the coverslips were mounted on glass slides with Mowiol. The cells were observed with a laser scanning confocal inverted microscope (Leica, TCS-SP) equipped with an argon-krypton laser. The samples were scanned under both 488- and 568-nm excitation wavelength for fluorescein isothiocyanate-conjugated secondary antibodies and Alexa 488-transferrin and for Texas Red-conjugated secondary antibodies, respectively. The images were acquired as single transcellular optical sections and averaged over at least 8 scans/frame.

Binding Experiments of Radiolabeled Pri308 Antibody-- Purified IgG Pri308 (50 µg) was radioiodinated in the presence of 0.5 nmol of sodium iodide (125INa 0.1 mCi/µl) for 10 min at room temperature by IODO-GEN (Pierce) according to the indirect labeling method as described previously (26). To prevent unspecific binding of the antibody, 500 µl of bovine serum albumin (2 mg/ml) was added to the reaction medium before purification by Sephadex-G25 chromatography (Amersham Biosciences). The radioactivity associated to intact IgGs was quantified by immunoprecipitation using protein G-Sepharose and represented 85-90% of the total radioactivity. For the cell binding assay, radioiodinated Pri308 antibody (~800,000 cpm/300 µl; ~3.5 nM) in Earle's buffer EDTA-free (25 mM Hepes, pH 7.4, 140 mM NaCl, 5 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 1 g/liter glucose, 0.2% bovine serum albumin) was added to confluent C13-NJ cells plated 48 h before in 24-well tissue culture plates. The incubations were performed at 37 °C for the indicated times for kinetics or 90 min for equilibrium studies. At steady state (i.e. 90 min at 37 °C), the incubation medium was rapidly removed, and the endocytosis of 125I-Pri308 was stimulated by incubating cells with 300 µl of Earle's buffer containing 500 µM CuSO4. At the end of the incubation time, the medium was removed, and the cells were rapidly washed twice with 1 ml of Earle's buffer. To estimate the amount of cell-sequestrated 125I-Pri308, the surface-bound radioactivity was removed by washing cells for 4 min at 37 °C with 500 µl of Earle's buffer pH4 containing 0.5 M NaCl (acid-NaCl buffer). In control conditions, the acid wash consistently removed ~95% of the cell surface radioactivity. Finally, the cells were lysed with 500 µl of 0.2 N NaOH, and the radioactivity was counted in a gamma  counter (Packard). The protein concentration was assayed by measuring the ratio of optical densities at 260 nm/280 nm. Nonspecific binding was determined in the presence of a large excess of unlabeled Pri308 (50 µg/ml; 1 µl/well) or of synthetic human prion peptide 106-128 (10 µM). In both cases, the nonspecific binding represented less than 8% of the total binding. Specific binding was calculated by subtracting nonspecific binding from total binding.

Assay for Release of PrP-sen from Cells-- Confluent cultures of C13-NJ or N2aS12 cells plated in 12-well tissue culture plates were washed four times with PBS containing 1% glucose, 10 µM bestatine, and a complete mixture of protease inhibitors EDTA-free (Roche Molecular Biochemicals) prior incubation in the presence or in the absence of filipin (5 µg/ml) at 37 °C. At the end of the incubation time, the culture media were collected and trichloroacetic acid-precipitated. The pellets were resuspended in 50 µl of denaturing loading buffer (65 mM Tris-HCl, pH 6.8, containing 5% SDS, 3% urea, 5% beta -mercaptoethanol, 10% glycerol, 0.05% bromphenol blue), boiled for 5 min, and loaded onto a 12% polyacrylamide gel. The proteins were separated by SDS-PAGE and then electroblotted onto a nitrocellulose membrane (Protran BA83; Schleicher & Schuell). The membranes were treated with 5% nonfat dry milk in TBST (20 mM Tris-HCl, pH 8, 100 mM NaCl, 0.1% Tween 20) and incubated overnight with the appropriate primary antibody at 4 °C. The blots were developed by using an enhanced chemoluminescence system (Roche Molecular Biochemicals) and exposed on x-ray film (X-Omat AR; Eastman Kodak Co.).

Assay for PrP-res Accumulation in N2aS12sc+-- N2aS12sc+ cells were seeded at 10-15% confluent density in a 24-well culture plate in Opti-MEM supplemented with 10% FBS. Four hours after plating at 37 °C, the cells were treated with the indicated concentrations of filipin, nystatin, or chlorpromazine for 4 days. Confluent cultures were lysed for 10 min at 4 °C in lysis buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 5 mM EDTA) and then centrifuged for 5 min at 3,000 × g. For detection of PrP-sen, one-tenth of the post-nuclear supernatants were directly mixed with the same volume of 2× denaturing loading buffer. For detection of PrP-res, the samples were digested with 20 µg of proteinase K/mg of total protein for 30 min at 37 °C. The digestion was stopped by adding Pefabloc® (1 mM) for 5 min before centrifugation at 20,000 × g for 90 min at room temperature. The pellets were resuspended in 30 µl of denaturing loading buffer, sonicated, boiled for 5 min, and loaded onto a 12% polyacrylamide gel. PrP-sen and partially digested PrP-res were assayed with SAF70 monoclonal antibody diluted 1:1000 in TBST. The blots were developed and exposed as described above. Densitometry was performed with National Institutes of Health Image software, computing at least four independent experiments, and the results are expressed as percentages of the control condition.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Copper-induced Subcellular Relocalization of Cell Surface PrP-sen-- A previous report showed that copper stimulates the endocytosis of PrP-sen in neuroblastoma cells. Using confocal laser microscopy, we further investigated the relocalization of cell surface PrP-sen induced by copper. Human microglia cells were incubated in the absence (Fig. 1A) or in the presence of 500 µM CuSO4 (Fig. 1B) for 30 min at 37 °C. After paraformaldehyde fixation, the cell surface PrP was assayed by incubation with Pri308 antibody and revealed by a Texas Red-conjugated secondary antibody under nonpermeabilized conditions (Fig. 1, A and B). Whereas the fluorescence was found associated to the cell surface of the microglia cells in control conditions, the copper incubation induced a significant disappearance of the cell-associated fluorescence (Fig. 1, A and B), suggesting the existence of a copper-induced PrP endocytosis mechanism. To further characterize this mechanism, microglia cells were first incubated with Pri308 for 90 min at 37 °C to specifically label the surface-bound PrP-sen and then submitted to copper stimulation. The confocal microscopy observations were performed on permeabilized cells. Copper-stimulated cells displayed an intense perinuclear fluorescent pattern, confirming that copper induced the relocation of PrP-sen from the cell membrane to intracellular compartments (Fig. 1C). At this point of our study, we cannot rule out the possibility that PrP-sen trafficking is disturb by the binding of Pri308. However, several lines of evidence will be provided later in the manuscript showing that the binding of Pri308 does not modify the copper-induced internalization of PrP.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Copper-induced relocalization of membranous PrP. A and B, Human microglia cells C13-NJ were incubated in the presence (B) or in the absence (A) of 500 µM CuSO4 for 30 min at 37 °C. The cells were rapidly rinsed and fixed with 3% paraformaldehyde for 20 min. Membrane-bound PrP was detected by incubating unpermeabilized cells with a 1:300 dilution of Pri 308 and a Texas Red-conjugated secondary antibody. Identical photomultiplicator values and parameters of the laser scanning confocal microscope were used in A and B. C, C13-NJ cells were incubated with Pri 308 in DMEM 10% FBS for 90 min. At the end of the incubation, 500 µM CuSO4 was added to the medium for 30 min at 37 °C. The cells were then rinsed and incubated for 45 min at 37 °C in DMEM containing 10% FBS. After paraformaldehyde fixation, Pri308 monoclonal antibody was detected with a secondary conjugated antibody on permeabilized cells as described under "Experimental Procedures." Scale bar, 15 µm.

Differentiation of Copper-induced PrP-sen Endocytosis through Coated and Noncoated Pathways-- To further investigate the pathway of copper-induced PrP-sen internalization, we performed immunocytochemical colocalization experiments both with anti-PrP monoclonal antibody and with a specific marker of the clathrin-dependent endocytosis pathway (transferrin-Alexa 488) and/or anti-caveolin-1 antibody to label the caveolae structures. As shown in Fig. 2, when endocytosis of PrP is induced by copper ions, PrP is relocalized into caveolin-1-positive intracellular compartments in human microglia cells. Moreover, the superimposed images clearly revealed the absence of colabeling fluorescence between the anti-PrP antibody and the transferrin receptor marker in both microglia and neuroblastoma cells. These results strongly suggest that copper-induced PrP endocytosis occurred via a caveolae-dependent pathway. Although it is well established that microglia cells contain caveolae and caveolin (27), no caveolin labeling was detected in mouse N2a by immunofluorescence confocal microscopy and Western blotting analysis (results not shown), in agreement with previous report (28).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Endocytosed PrP colocalizes with caveolae-like domains and not with transferrin. Human microglia and mouse neuroblastoma cells were incubated for 2 h at 37 °C with Pri308 or R30 antibodies, respectively. Forty minutes before the end of the incubation time, CuSO4 (500 µM) and Alexa 488-transferrin (50 µg/ml) were added as indicated. The cells were then rinsed, fixed, and permeabilized, and the presence of anti-PrP antibodies was revealed with a Texas Red-conjugated secondary antibody. Caveolin-1 protein was detected with an anti-caveolin-1 antibody and a fluorescein isothiocyanate-conjugated secondary antibody. No caveolin-1 labeling could be detected into N2a cells (not shown). The yellow color indicates the red and green colabeling. The arrowheads show clusters of colabeling. Scale bar, 15 µm.

Effects of Filipin, Nystatin, and Chlorpromazine on the Relocalization of PrP-sen Induced by Copper-- In the absence of marker of the caveolae-dependent endocytosis pathway in neuroblastoma cells, we examined the effect of two classes of drugs on PrP-sen endocytosis. Sterol-binding agents such as filipin and nystatin bind to cholesterol, a major component of glycolipid microdomains and caveolae, and disrupt caveolar structure and function (27, 29). On the other hand, chlorpromazine inhibits the clathrin-dependent pathway (30, 31). Human microglia and 3F4-PrP expressing neuroblastoma cells were incubated in the absence or in the presence of filipin, nystatin, or chlorpromazine prior to copper stimulation for 30 min and paraformaldehyde fixation. The cell surface PrP-sen molecules were monitored by staining with Pri308 antibody. The observations were performed by confocal laser microscopy on nonpermeabilized cells. In control conditions, the cells exhibited a loss of fluorescence at the plasma membrane after copper stimulation, confirming the endocytosis of PrP-sen from the surface to the inside of the cell (Fig. 3A). In contrast, fluorescence was found only at the cell surface of filipin- or nystatin-treated cells, indicating that these cells were unable to significantly internalize PrP-sen after copper stimulation. In contrast, chlorpromazine-treated cells displayed a loss of cell surface fluorescence similar to that of untreated cells. Thus, the results with filipin and nystatin indicated that copper-induced PrP endocytosis occurred through cholesterol-rich microdomains including the possible involvement of caveolae in both human microglia and neuroblastoma cells. The interaction of filipin with cholesterol and its inhibitory effects on the copper-induced PrP-sen endocytosis can be demonstrated in both caveolin-expressing or caveolin-devoid cells.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of filipin, nystatin, and chlorpromazine on the relocalization of cell surface-bound PrP and transferrin receptors. A, C13-NJ and 3F4-N2a cells were treated with 5 µg/ml filipin or 50 µg/ml nystatin for 15 min or with 5 µg/ml chlorpromazine for 30 min at 37 °C. CuSO4 (500 µM) was then added to the incubation medium for 30 min. After a rapid wash with PBS, surface-bound PrP was revealed on unpermeabilized cells with Pri308 and Texas Red-conjugated secondary antibody. Identical photomultiplicator values and parameters of the laser scanning confocal microscope were used for all of the panels. B, 3F4-N2a cells were preincubated with DMEM containing 1% bovine serum albumin for 90 min at 37 °C. The cells were then incubated in the absence (panels a and a') or in the presence of 5 µg/ml filipin (panels b and b') or 5 µg/ml chlorpromazine for 30 min (panels c and c'). The incubation medium was removed, and the cells were incubated in the presence of a solution of Alexa 488-transferrin for 30 min at 37 °C. The cells were then rinsed, fixed with 3% paraformaldehyde, and observed with a laser scanning confocal microscope. Panels a, b, and c, confocal microscopy images. Panels a', b', and c', overlay representations of confocal and transmission microscopy observations.

Knowing that transferrin receptors are internalized via clathrin-coated pits, we further compared the distribution of Alexa 488-transferrin into neuroblastoma cells in control, filipin-treated, and chlorpromazine-treated cells. As shown in Fig. 3B, control and filipin-treated cells exhibited a largely perinuclear fluorescence pattern with a concomitant loss of plasma membrane labeling. In contrast, Alexa 488-transferrin fluorescence was found predominantly at the cell surface of chlorpromazine-treated cells, indicating that these cells did not internalize transferrin receptors. Other fields from chlorpromazine-treated neuroblastoma cells occasionally showed some internalized Alexa 488-transferrin fluorescence; however, the pattern was diffuse and remained in the region underlying the plasma membrane. In summary, we confirmed that transferrin receptor, a typical clathrin-dependent endocytosis pathway, was insensitive to filipin and also to nystatin treatment (data not shown), whereas it could be efficiently inhibited by chlorpromazine.

Binding of 125I-Pri308 Antibody to Human Microglia Cells (C13-NJ)-- The goal of these studies was to characterize the kinetic parameters of PrP-sen internalization induced by copper using the approach of binding of radiolabeled monoclonal antibody Pri308 to the cell surface. This antibody was chosen from a panel of antibodies developed against PrP essentially because Pri308 is able to recognize the human PrP-sen in native conditions. The binding of the 125I-Pri308 antibody to the cell surface was specific because the radiolabeled IgG bound can be displaced by 10 µM of synthetic peptide sequence 106-128 or by an excess of unlabeled Pri308 (Fig. 4) but not by a 100-fold excess of unlabeled nonimmune mouse IgG (data not shown). Moreover, the binding of 125I-Pri308 on confluent mouse PrP-overexpressing N2a cells was similar to nonspecific binding (data not shown). The binding equilibrium of 125I-Pri308 was reached by 90 min at 37 °C. In subsequent experiments, the cells were incubated with 125I-Pri308 for 90 min at 37 °C, then rapidly rinsed, and incubated in the presence or in the absence of 500 µM of CuSO4 for different times. At the end of the incubation time, the cells were submitted to a hyperosmotic acid wash for 4 min. In the presence of copper, the acid wash-resistant binding increased rapidly, reached a plateau (~38% of total binding) at 30 min, and was stable for at least 60 min. In the absence of cooper, the acid wash-resistant binding never exceeded 5% of the total binding (Fig. 4, inset), demonstrating that IgG binding did not provoke PrP-sen internalization by itself. Using this procedure, we determined that the concentration of copper able to induce 50% of maximal internalization was 125 µM (data not shown). After 30 min at 37 °C, 500 µM ZnSO4, NiCl2, and CoCl2 also stimulated the endocytosis of 25I-Pri308 antibody into human microglia cells by 25, 14, and 10% of the total binding, respectively; no effect was seen with MnCl2 and FeSO4 (data not shown).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 4.   Association and copper-induced endocytosis kinetics of 125I-Pri308 antibody to human microglia cells. Confluent C13-NJ cells plated into 24-well tissue culture plates were incubated at 37 °C in Earle's buffer containing 125I-Pri308 monoclonal antibody (800 000cpm/300 µl) in the absence (black circles) or in the presence (open circles) of a large excess of unlabeled Pri308 or 10 µM synthetic peptide P106-128. At the indicated times, the cells were rapidly washed twice with 1 ml of Earle's buffer and lysed with 500 µl of 0.2 N NaOH, and the radioactivity bound to cells was counted. Inset, C13-NJ cells were incubated in Earle's buffer containing radiolabeled Pri308 antibody for 90 min at 37 °C. Then the incubation medium was rapidly removed, and 300 µl of Earle's buffer was added in the absence (open squares) or in the presence (black squares) of 500 µM CuSO4. At the indicated times, the cells were treated with Earle's buffer, pH 4, containing 0.5 M NaCl for 4 min at 37 °C. The results are expressed as the percentages of acid wash binding compared with the associated cell-specific binding. The results are means of six independent experiments where each point is the average of duplicate determinations.

Effects of Filipin and Chlorpromazine on Binding and Copper-induced Internalization of 125I-Pri308 Antibody to Human Microglia Cells-- We next examined the effects of filipin and chlorpromazine on both the 125I-Pri308 specific binding and the copper-induced endocytosis assays to human microglia cells. As expected, the cells treated with filipin exhibited a significant decrease in the amount of acid wash-resistant binding of 125I-Pri308 antibody after copper stimulation (Fig. 5A, right panel). Surprisingly, the filipin treatment also induced a decrease of the specific binding of 125I-Pri308 antibody in a time-dependent manner (Fig. 5A, left panel). One hour of filipin treatment resulted in a 60% decrease of the 125I-Pri308-specific binding (Fig. 5A). The inhibition of the cell surface binding of radiolabeled IgG by filipin was concentration-dependent (Fig. 5B). In the course of these experiments, there was no evidence for cytotoxicity or reduced protein synthesis in human microglia cultures exposed to filipin. Chlorpromazine had no effect on the 125I-Pri308 antibody-specific binding to C13-NJ cells nor on copper-induced endocytosis mechanism (Fig. 5A). In summary, we show that filipin decreases the cell surface-specific binding of 125I-Pri308 antibody and inhibits the copper-induced endocytosis of the remaining PrP-sen molecules.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of filipin and chlorpromazine on the surface-bound and internalized 125I-Pri308 antibody. C13-NJ were incubated at 37 °C in Earle's buffer containing radiolabeled Pri308 (800,000 cpm/300 µl) for 90min. Filipin or chlorpromazine (chlorpro) were added to the incubation medium 5, 15, and 30 min prior the end of the radiolabeled IgG incubation time at a final concentration of 5 µg/ml. The medium was then removed and replaced by 500 µl of Earle's buffer containing 500 µM CuSO4 and 5 µg/ml of filipin or chlorpromazine as indicated for an additional incubation time of 30 min at 37 °C. Finally, the cells were treated with Earle's buffer, pH 4, containing 0.5 M NaCl for 4 min at 37 °C (gray histograms) or by two washes with 1 ml of Earle's buffer (white histograms). The radioactivity was recovered by scraping the cells with 500 µl of 0.2 N NaOH and counted. A, representation of the effects of drugs on cell-associated radiolabeled Pri308 binding as a function of time. The results are expressed as percentages of specific binding (i.e. total binding - nonspecific binding) of the control experiment performed in the absence of drug (left panel). For endocytosis experiments (right panel), the results are expressed as follows: acid wash-resistant binding × 100/cell-associated specific binding. B, dose-response of filipin on the radiolabeled IgG binding. The results are the means of five independent experiments where each point is the average of duplicate determinations.

Filipin Induces Release of PrP-sen from Cell Surface of Human Microglia and Mouse Neuroblastoama Cells-- The decrease in cell surface-specific binding of 125I-Pri308 antibody induced by filipin could be due to a release of PrP-sen from the cell surface into the culture medium. To investigate this possibility, C13-NJ and 3F4-N2a cells were treated with filipin, and the culture media were assayed for the presence of PrP-sen by Western blot. As shown in Fig. 6, treatment of both type of cells by filipin induces the release of fully matured PrP-sen into the medium in a time-dependent manner. In these experiments, if the mixture of protease inhibitors was omitted, the amino-terminal epitope of SAF32 antibody was rapidly destroyed (data not shown), whereas the epitopes of SAF70 and Pri308 remained intact. In summary, filipin induces a continuous release of membrane-bound PrP-sen into the medium.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 6.   Kinetics of release of surface-bound PrP induced by filipin treatment. Shown is a representative experiment performed by treating C13-NJ or N2aS12 cells in the absence (control) or in the presence of 5 µg/ml of filipin at 37 °C in PBS containing 1% glucose and a mixture of inhibitors. At the indicated times, the incubation medium was collected and trichloroacetic acid-precipitated. The pellets were resuspended in denaturating loading buffer and analyzed by Western blot. PrP was revealed with the indicated anti-PrP antibodies and developed with the enhanced chemoluminescence system. MW, molecular mass.

Inhibition of PrP-res Formation in N2a S12sc+ Cells by Filipin-- Because filipin treatment results in a release of cell surface PrP-sen, we asked whether filipin could also inhibit the PrP-res accumulation in chronically infected N2a S12sc+ cells. N2a S12sc+ cells were incubated continuously for 4 days with various concentrations of filipin, and then cell lysates were assayed for the presence of proteinase K-resistant isoforms of PrP (Fig. 7A). Alternatively, discontinuous treatment of cells was performed with filipin for 30 min twice a day for 4 days (data not shown). In both types of treatment, filipin reduced the amount of detectable PrP-res in a dose-dependent manner with an IC50 of 1.25 µg/ml i.e. 2 µM (Fig. 7B). No cytotoxicity was observed within the range of filipin concentrations used in these experiments. Moreover, PrP-sen synthesis was not affected by the filipin treatment (data not shown). As described previously (32), we observed that chlorpromazine also inhibits PrP-res accumulation into our N2a S12sc+ cells system (data not shown).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of filipin on the accumulation of PrP-res in infected N2aS12. A, immunoblot of a representative experiment performed by treating cells in the absence (0) or in the presence of the indicated concentrations of filipin for 4 days. PrP-res was detected with the monoclonal antibody SAF70. B, dose-response curve of the inhibition of PrP-res accumulation induced by filipin. The data represent the means of four independent experiments ± S.D. (bars) and were expressed as relative quantities of PrP-res in the presence of the drug compared with the control culture. MW, molecular mass.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present report, we investigate the mechanism of PrP endocytosis induced by copper ions in both overexpressing mouse PrP neuroblastoma and endogenous PrP expressed human microglia cells. Having quantitatively assayed the surface-bound and the caveolae-mediated trafficking pathway of PrP, we showed that disruption of cholesterol-rich domains could prevent PrP-res accumulation.

PrP trafficking has been previously investigated by indirect procedures using cell surface iodination or biotinylation (20, 33). In the radiolabeling IgG binding assay used in this study, several technical differences should be pointed out. First, the use of monoclonal antibody Pri308, which recognizes the 106-126 epitope of the human PrP sequence, allows us to selectively measure the unprocessed PrP molecules. Indeed, it has been shown that PrP-sen is submitted to a physiological proteolytic process occurring around amino acid residues 110-111 (34, 35), giving rise to disruption of the Pri308-recognized epitope. A significant part of PrP-sen molecules present at the surface of cells are amino terminus-shortened and thus are not taken into account in our radiolabeled IgG assay. Second, in light of studies showing that bivalent antibodies can alter the normal endocytotic pathway of receptor (36, 37), we could not be sure a priori that this approach accurately reflected PrP trafficking. Several lines of evidence show that binding of whole IgG to PrP does not induce internalization. In the absence of copper stimulation, no acid wash-resistant (i.e. internalized) 125I-Pri308 was measured in the course of the incubations. Our results were consistent with those obtained using the cell surface iodination/biotinylation assay, in terms of endocytosis kinetics, divalent ions efficiencies, and concentrations of copper required for induction of PrP endocytosis (20, 33). Moreover, a similar approach has been successfully used to characterize the trafficking of cell surface amyloid beta -protein precursor (38). Together, these observations strongly suggested that the binding of Pri308/PrP does not modify the copper-induced endocytosis of PrP. In the future, this direct approach could be a convenient way to determine whether the identified mutations within PrP in human hereditary TSE affect PrP trafficking.

Previous reports have shown a subcellular localization of surface-bound PrP-sen in caveolae membranous domains (6, 18). However, other investigators have reported that endocytosis of chicken PrP-expressing N2a cells is mediated via clathrin-coated pits (28). These discrepancies could be due to the high divergence between mammalian and chicken PrP sequences (~30% homology) and to the considerable overexpression of exogenous PrP molecules into neuroblastoma cells. Moreover, authors have well studied unstimulated endocytosis of PrP but failed to characterize the copper-stimulated endocytosis pathway (20, 28). The possibility that copper-induced endocytosis and unstimulated turnover of PrP take out different endocytosis pathways cannot be ruled out.

PrP-sen has been shown to bind copper ions in vitro and in vivo likely via the octarepeats amino-terminal region encompassing residues 60-91 (19, 39). More recently, Jackson et al. (40) have accurately characterized two classes of copper-binding sites within the human PrP sequence. The first one is located in the amino-terminal octapeptide repeats and specifically binds copper ions with a Kd value of 10-14 M. The second copper-binding site is included in the carboxyl-terminal domain of PrP and interacts with various divalent metals with a micromolar affinity. Thus, it is likely that PrP endocytosis induced by copper, nickel, zinc, and cobalt in the micromolar range is mediated by the low affinity metal ion-binding sites. At variance with this line of reasoning, deletion of the amino-terminal region of PrP (Delta 25-91) including the octapeptide repeats has been claimed to lead to the abolishment of copper-induction PrP endocytosis (20, 41). The minimal concentration of copper released from synaptosomes into the extracellular space upon depolarization conditions has been estimated to be 100 µM (42, 43). Thus, the physiological relevance of the low affinity metal ion-binding sites of PrP is plausible. However, the existence of natural ligands not yet identified capable of interacting with PrP with a high affinity and inducing its internalization cannot be ruled out. Interestingly, direct interactions between PrP and cellular glycosaminoglycans have been reported (44, 45) as well as the induction of PrP endocytosis by sulfated glycans (46).

In our attempts to further characterize the copper-stimulated endocytosis pathway, we used two classes of drugs described as specific blockers of caveolae- and clathrin-dependent pathways (47). Sterol-binding agents such as filipin and nystatin bind to cholesterol, a major component of glycolipid microdomains and caveolae, and disrupt caveolae structure and function (27, 29). In contrast, cationic amphiphilic drugs such as chlorpromazine act on the clathrin-dependent pathway and inhibit receptor-mediated endocytosis by reducing the number of coated pit-associated receptors at the cell surface (30, 31). In our cell models, filipin efficiently blocks the copper-stimulated endocytosis of PrP-sen. Moreover, under copper-induced internalization conditions, PrP-sen labeling never colocalizes with transferrin, a marker of the clathrin-dependent pathway, and colocalizes with caveolin. Taken together, our results strongly suggest that copper-stimulated PrP endocytosis occurs via lipid rafts in both neuronal and non-neuronal cells. Surprisingly, filipin also induces the release of fully matured PrP molecules from the cell surface, likely by interacting with membrane sterols. Based on its sterol binding properties, we hypothesize that filipin alters the caveolar structures, resulting in both inhibition of endocytosis process and release of GPI-anchored PrP molecules. To our knowledge, this is the first report showing that filipin is capable of releasing a GPI-anchored protein.

Acute or chronic filipin treatments of scrapie-infected N2a efficiently inhibit PrP-res accumulation. It was proposed that the PrP-sen/PrP-res conversion process could be compared with a autocatalytic polymerization reaction (48) occurring somewhere between the cell surface and the organelles of the endocytic pathway. Thus, decreasing the level of PrP-sen substrate leads to an inhibition of PrP-res formation. Both inhibition of endocytosis of PrP and release of membrane-bound PrP induced by filipin could produce additional effects by removing the substrate available for conversion. Note that phosphatidylinositol-specific phospholipase C treatment inhibits PrP-res formation into infected N2a cells likely by cleavage of the GPI anchor and release of PrP from the cell surface (4). There is a lot of evidence showing that filipin, amphotericin B, and nystatin, which belong to the same polyene antibiotic family, interact with cholesterol (for review see Ref. 49). Although amphotericin B is one of the most potent anti-scrapie agents, its mechanism of action remains unclear (16, 50). In our radiolabeled IgG assays, no effect of amphotericin B was found on PrP endocytosis and on the release of cell surface PrP, suggesting that its mechanism of action differs from that of filipin. The same statement has been made concerning chlorpromazine, which inhibits PrP-res formation in infected N2a (32)2 remains without effect on surface-bound PrP relocalization. The anti-scrapie mechanisms of action of both chlorpromazine and amphotericin B remain to be characterized.

It has been shown that caveolae-like domains isolated from infected N2a contain PrP-res (6). However, we never detected PrP-res in the culture medium of infected N2a treated by filipin, suggesting that the anchorage of PrP-res at the cell surface may be insensitive to disruption of lipid rafts.

In conclusion, our results further document the crucial role played by caveolae-like domains in the cellular events leading to PrP-res formation. The identification of drugs such as filipin that disturb the trafficking of PrP underscores the role of lipid rafts in the pathogenesis of TSE and may provide new therapeutic strategies.

    ACKNOWLEDGEMENTS

We are grateful to Dr. Caughey and Dr. Schätzl for providing the rabbit polyclonal antibody R30 and the neuroblastoma 3F4PrP-expressing cells, respectively. Very special thanks are due to Pr. Jean-Pierre Vincent for critical reading of the manuscript, Peggy Richard and Roxane Pichot for technical assistance, and Stephane Martin for confocal microscopy advice.

    FOOTNOTES

* This work was supported in part by French government grants from the "Action Concertée Incitive" Jeunes Chercheurs (2000) and by the "Groupement d'Intèrêt Scientifique" Infections à Prions (2001).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: IPMC, CNRS, 660 Route des Lucioles, 06560 Valbonne, France. Tel.: 334-93-95-77-67; Fax: 334-93-95-77-08; E-mail: chabry@ipmc.cnrs.fr.

Published, JBC Papers in Press, May 6, 2002, DOI 10.1074/jbc.M203248200

2 M. Marella and J. Chabry, unpublished data.

    ABBREVIATIONS

The abbreviations used are: TSE, transmissible spongiform encephalopathy(ies); GPI, glycosylphosphatidylinositol; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; SAF, scrapie-associated fibrils; PBS, phosphate-buffered saline; HS, horse serum.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hope, J., Morton, L. J. D., Farquhar, C. F., Multhaup, G., Beyreuther, K., and Kimberlin, R. H. (1986) EMBO J. 5, 2591-2597[Medline] [Order article via Infotrieve]
2. Pan, K.-M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R. J., Cohen, F. E., and Prusiner, S. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10962-10966[Abstract/Free Full Text]
3. Oesch, B., Westaway, D., Walchli, M., Mckinley, M. P., Kent, S. B., Aebersold, R., Barry, R. A., Tempst, P., Teplow, D. B., Hood, L. E., Prusiner, S. B., and Weissmann, C. (1985) Cell 40, 735-746[CrossRef][Medline] [Order article via Infotrieve]
4. Caughey, B., and Raymond, G. J. (1991) J. Biol. Chem. 266, 18217-18223[Abstract/Free Full Text]
5. Stahl, N., Baldwin, M. A., Teplow, D. B., Hood, L., Gibson, B. W., Burlingame, A. L., and Prusiner, S. B. (1993) Biochemistry 32, 1991-2002[CrossRef][Medline] [Order article via Infotrieve]
6. Vey, M., Pilkuhn, S., Wille, H., Nixon, R., DeArmond, S. J., Smart, E. J., Anderson, R. G., Taraboulos, A., and Prusiner, S. B. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14945-14949[Abstract/Free Full Text]
7. Madore, N., Smith, K. L., Graham, C. H., Jen, A., Brady, K., Hall, S., and Morris, R. (1999) EMBO J. 18, 6917-6926[CrossRef][Medline] [Order article via Infotrieve]
8. Brown, D. A., and Rose, J. K. (1992) Cell 68, 533-544[CrossRef][Medline] [Order article via Infotrieve]
9. Sargiacomo, M., Sudol, M., Tang, Z., and Lisanti, M. P. (1993) J. Cell Biol. 122, 789-807[Abstract/Free Full Text]
10. Kartenbeck, J., Stukenbrok, H., and Helenius, A. (1989) J. Cell Biol. 109, 2721-2729[Abstract/Free Full Text]
11. Anderson, H. A., Chen, Y., and Norkin, L. C. (1996) Mol. Biol. Cell 7, 1825-1834[Abstract]
12. Lehmann, S., Milhavet, O., and Mange, A. (1999) Biomed. Pharmacother. 53, 39-46[CrossRef][Medline] [Order article via Infotrieve]
13. Caughey, B., Raymond, G. J., Ernst, D., and Race, R. E. (1991) J. Virol. 65, 6597-6603[Abstract/Free Full Text]
14. Borchelt, D. R., Taraboulos, A., and Prusiner, S. B. (1992) J. Biol. Chem. 267, 16188-16199[Abstract/Free Full Text]
15. Baron, G. S., Wehrly, K., Dorward, D. W., Chesebro, B., and Caughey, B. (2002) EMBO J. 21, 1031-1040[CrossRef][Medline] [Order article via Infotrieve]
16. Mange, A., Nishida, N., Milhavet, O., McMahon, H. E., Casanova, D., and Lehmann, S. (2000) J. Virol. 74, 3135-3140[Abstract/Free Full Text]
17. Taraboulos, A., Scott, M., Semenov, A., Avraham, D., Laszlo, L., and Prusiner, S. B. (1995) J. Cell Biol. 129, 121-132[Abstract/Free Full Text]
18. Kaneko, K., Vey, M., Scott, M., Pilkuhn, S., Cohen, F. E., and Prusiner, S. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2333-2338[Abstract/Free Full Text]
19. Brown, D. R., Qin, K., Herms, J. W., Madlung, A., Manson, J., Strome, R., Fraser, P. E., Kruck, T., von Bohlen, A., Schulz-Schaeffer, W., Giese, A., Westaway, D., and Kretzschmar, H. (1997) Nature 390, 684-687[Medline] [Order article via Infotrieve]
20. Pauly, P. C., and Harris, D. A. (1998) J. Biol. Chem. 273, 33107-33110[Abstract/Free Full Text]
21. Manson, J. C., Clarke, A. R., Hooper, M. L., Aitchison, L., Mcconnell, I., and Hope, J. (1994) Mol. Neurobiol. 8, 121-127[Medline] [Order article via Infotrieve]
22. Demart, S., Fournier, J. G., Creminon, C., Frobert, Y., Lamoury, F., Marce, D., Lasmezas, C., Dormont, D., Grassi, J., and Deslys, J. P. (1999) Biochem. Biophys. Res. Commun. 265, 652-657[CrossRef][Medline] [Order article via Infotrieve]
23. Janabi, N., Peudenier, S., Heron, B., Ng, K. H., and Tardieu, M. (1995) Neurosci. Lett. 195, 105-108[CrossRef][Medline] [Order article via Infotrieve]
24. Gilch, S., Winklhofer, K. F., Groschup, M. H., Nunziante, M., Lucassen, R., Spielhaupter, C., Muranyi, W., Riesner, D., Tatzelt, J., and Schätzl, H. M. (2001) EMBO J. 20, 3957-3966[CrossRef][Medline] [Order article via Infotrieve]
25. Nishida, N., Harris, D. A., Vilette, D., Laude, H., Frobert, Y., Grassi, J., Casanova, D., Milhavet, O., and Lehmann, S. (2000) J. Virol. 74, 320-325[Abstract/Free Full Text]
26. Riske, F., Hakimi, J., Mallamaci, M., Griffin, M., Pilson, B., Tobkes, N., Lin, P., Danho, W., Kochan, J., and Chizzonite, R. (1991) J. Biol. Chem. 266, 11245-11251[Abstract/Free Full Text]
27. Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R., and Anderson, R. G. (1992) Cell 68, 673-682[CrossRef][Medline] [Order article via Infotrieve]
28. Shyng, S. L., Heuser, J. E., and Harris, D. A. (1994) J. Cell Biol. 125, 1239-1250[Abstract/Free Full Text]
29. Rothberg, K. G., Ying, Y. S., Kamen, B. A., and Anderson, R. G. (1990) J. Cell Biol. 111, 2931-2938[Abstract/Free Full Text]
30. Wang, L. H., Rothberg, K. G., and Anderson, R. G. (1993) J. Cell Biol. 123, 1107-1117[Abstract/Free Full Text]
31. Sofer, A., and Futerman, A. H. (1995) J. Biol. Chem. 270, 12117-12122[Abstract/Free Full Text]
32. Korth, C., May, B. C., Cohen, F. E., and Prusiner, S. B. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9836-9841[Abstract/Free Full Text]
33. Shyng, S. L., Huber, M. T., and Harris, D. A. (1993) J. Biol. Chem. 268, 15922-15928[Abstract/Free Full Text]
34. Chen, S. G., Teplow, D. B., Parchi, P., Teller, J. K., Gambetti, P., and Autilio-Gambetti, L. (1995) J. Biol. Chem. 270, 19173-19180[Abstract/Free Full Text]
35. Vincent, B., Paitel, E., Frobert, Y., Lehmann, S., Grassi, J., and Checler, F. (2000) J. Biol. Chem. 275, 35612-35616[Abstract/Free Full Text]
36. Anderson, R. G., Brown, M. S., Beisiegel, U., and Goldstein, J. L. (1982) J. Cell Biol. 93, 523-531[Free Full Text]
37. Ukkonen, P., Lewis, V., Marsh, M., Helenius, A., and Mellman, I. (1986) J. Exp. Med. 163, 952-971[Abstract/Free Full Text]
38. Koo, E. H., Squazzo, S. L., Selkoe, D. J., and Koo, C. H. (1996) J. Cell Sci. 109, 991-998[Abstract]
39. Stockel, J., Safar, J., Wallace, A. C., Cohen, F. E., and Prusiner, S. B. (1998) Biochemistry 37, 7185-7193[CrossRef][Medline] [Order article via Infotrieve]
40. Jackson, G. S., Murray, I., Hosszu, L. L., Gibbs, N., Waltho, J. P., Clarke, A. R., and Collinge, J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8531-8535[Abstract/Free Full Text]
41. Sumudhu, W., Perera, S., and Hooper, N. M. (2001) Curr. Biol. 11, 519-523[CrossRef][Medline] [Order article via Infotrieve]
42. Kardos, J., Kovacs, I., Hajos, F., Kalman, M., and Simonyi, M. (1989) Neurosci. Lett. 103, 139-144[CrossRef][Medline] [Order article via Infotrieve]
43. Brown, D. R. (2001) Trends Neurosci. 24, 85-90[CrossRef][Medline] [Order article via Infotrieve]
44. Priola, S. A., and Caughey, B. (1994) Mol. Neurobiol. 8, 113-120[Medline] [Order article via Infotrieve]
45. Caughey, B., Brown, K., Raymond, G. J., Katzenstein, G. E., and Thresher, W. (1994) J. Virol. 68, 2135-2141[Abstract/Free Full Text]
46. Shyng, S.-L., Lehmann, S., Moulder, K. L., and Harris, D. A. (1995) J. Biol. Chem. 270, 30221-30229[Abstract/Free Full Text]
47. Orlandi, P. A., and Fishman, P. H. (1998) J. Cell Biol. 141, 905-915[Abstract/Free Full Text]
48. Lansbury, P. T., Jr., and Caughey, B. (1996) Curr. Biol. 6, 914-916[CrossRef][Medline] [Order article via Infotrieve]
49. Holz, R. W. (1974) Ann. N. Y. Acad. Sci. 235, 469-479[CrossRef][Medline] [Order article via Infotrieve]
50. Demaimay, R., Adjou, K. T., Beringue, V., Demart, S., Lasmezas, C. I., Deslys, J. P., Seman, M., and Dormont, D. (1997) J. Virol. 71, 9685-9689[Abstract]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
R. Kumar, D. McClain, R. Young, and G. A. Carlson
Cholesterol transporter ATP-binding cassette A1 (ABCA1) is elevated in prion disease and affects PrPC and PrPSc concentrations in cultured cells
J. Gen. Virol., June 1, 2008; 89(6): 1525 - 1532.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
R. Linden, V. R. Martins, M. A. M. Prado, M. Cammarota, I. Izquierdo, and R. R. Brentani
Physiology of the Prion Protein
Physiol Rev, April 1, 2008; 88(2): 673 - 728.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Campana, A. Caputo, D. Sarnataro, S. Paladino, S. Tivodar, and C. Zurzolo
Characterization of the Properties and Trafficking of an Anchorless Form of the Prion Protein
J. Biol. Chem., August 3, 2007; 282(31): 22747 - 22756.
[Abstract] [Full Text] [PDF]